Ignite Creation Date:
2024-05-05 @ 5:18 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00429065
Status:
UNKNOWN
Last Update Posted:
2007-01-31
First Post:
2007-01-30
Brief Title:
Treatment of Good Prognosis BCL-6 Negative Diffuse Large Cell Lymphoma With CHOP-R in Patients 61 Years Old
Sponsor:
Instituto Nacional de Cancerologia de Mexico
Organization:
Instituto Nacional de Cancerologia de Mexico
Study Overview
Official Title:
Selection of Young Patients 61 Years With Good Prognosis Diffuse Large B Cell Lymphoma According to the Immunophenotype BCL-6 Negative to be Treated With Chemoimmunotherapy With R-CHOP A Pilot Study
Status:
UNKNOWN
Status Verified Date:
2007-01
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine whether a specific subtype of lymphoma responds optimally to treatment with rituximab and chemotherapy
Detailed Description:
Treatment with rituximab and chemotherapy R-CHOPis the accepted treatment for young patients with diffuse large B cell Non-Hodgkins Lymphoma However not every patient benefits with this expensive therapy Recent data suggest that patients with BCL-6 negative lymphoma are more sensitive to Rituximab therapy It is also known that patients with high-intermediate and high IPI risk does not benefit form standard three weekly CHOP chemotherapy
In this study we intend to define a subgroup of patients in whom this therapy will be of maximum benefit
We will prospectively treat a group of patients with the following characteristics
60 years old low and low intermediate IPI risk BCL-6 negative B-cell NHL Treatment regimen R-CHOP standard dosis for 8 cycles
In this study we intend to define a subgroup of patients in whom this therapy will be of maximum benefit
We will prospectively treat a group of patients with the following characteristics
60 years old low and low intermediate IPI risk BCL-6 negative B-cell NHL Treatment regimen R-CHOP standard dosis for 8 cycles
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None